SCHEMBL1107878

SCHEMBL1107878

c1ccc(-c2cccc(-c3nnc(-c4ccc5c(ccc6nc(-c7nnc(-c8cccc(-c9ccccc9)n8)s7)ccc65)n4)s3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ TDO2 P48775 1/20 0.43
▸ PIM1 P11309 1/20 0.41
▸ PIM3 Q86V86 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ASIC3 Q9UHC3 1/20 0.41
▸ LIMK1 P53667 2/20 0.38
▸ ACHE P22303 1/20 0.37
▸ NQO2 P16083 1/20 0.36
▸ ESR1 P03372 2/20 0.36
▸ ESR2 Q92731 2/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ MAPKAPK2 P49137 1/20 0.36
▸ CYP2C9 P11712 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1107895 0.88 RAB9A (0.67) RAB9AMEN1KMT2APIM1PIM3
SCHEMBL1107880 0.84 TOP1 (0.39) RAB9AMEN1KMT2AKDM4E
SCHEMBL13999308 0.84 RAB9A (0.36) RAB9AMEN1KMT2ATDO2PIM1
SCHEMBL1107890 0.83 KDM4E (0.57) RAB9ANPC1MAPTKDM4EATM
SCHEMBL1107852 0.83 KDM4E (0.57) RAB9ANPC1MAPTKDM4EATM
SCHEMBL1107892 0.83 RAB9A (0.59) RAB9AMEN1KMT2APIM1PIM3
SCHEMBL1107961 0.82 CTSS (0.47) MEN1KMT2APIM1PIM3KDM4E
SCHEMBL1107903 0.82 RAB9A (0.53) RAB9AMEN1KMT2APIM1PIM3
SCHEMBL1107949 0.82 MEN1 (0.43) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL1107866 0.81 RAB9A (0.57) RAB9AMEN1KMT2APIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153277-B2 Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-8153277-B2 Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 — — US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE OXA1L, SLCO4C1, SLCO2B1 RAB9A 2662/4885MEN1 1449/4885KMT2A 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback